EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Anagenics Ltd (AN1) fair value: what the stock is really worth

We calculate from audited financials what Anagenics Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Sep 13, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Consumer Defensive · AU · ISIN AU0000198095

AL Thin data Sep 13, 2026

Anagenics Ltd

AN1 · AU

Weak valuationQuality is weak on top of the rich price.

!Fair value A$0.0053 · Overvalued (−12%)
!Quality 42/100
!Weak Growth (revenue 5y −8.5 %/yr)
!Loss-making · -13.4% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/11)
!Narrow moat 16/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 18 out of 100
Watch Anagenics Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.1060 A$0.0040 Fair Value A$0.0053 Oct 2020 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range A$0.0040 – A$0.1060 · the A$0.0060 price screens above the A$0.0053 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.

Follow Anagenics in your weekly email

Every Wednesday you see whether Anagenics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name.

Show more

Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

Stock analysis

Anagenics Ltd (AN1) currently trades at A$0.0060, while our model-based Fair Value estimate is A$0.0053, implying the stock looks roughly 13.2% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Consumer Defensive sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Anagenics Ltd reported revenue of A$4.7M in FY2025 versus A$5.8M in FY2021, a compound −5.0%/yr. Reported net income was −A$1.2M in FY2025.

Key figures

Market cap A$5.9M · P/S ratio 1.22 · Net margin −26.0% · Return on equity −28.5% · Return on assets (EBIT) −41.7% · Operating margin 6.8% · Revenue (TTM) A$4.8M · Revenue growth (YoY) −10.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 50% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −20% fair-value upside, at −12%, AN1 screens cheaper than that median.

Notify me when AN1 reaches fair value

Put AN1 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 42/100

Of which business quality 43 · Market factors (momentum, volatility) 46

Profitability 36
Margins and returns on capital today
Quality Growth 55
Are margins and returns improving?
Cashflow 38
Earnings quality: real cash, not paper profit
Fin. Strength 45
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 42
Price trend over the last 3–12 months (market factor)
52W Momentum 48
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−56.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.5%
Start year 2020 (pandemic). Over 10 years: +9.9% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−64.3% (2020) → −27.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

AN1 screens 13% overvalued. Compare with Colgate-Palmolive Company →

Compare Anagenics Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 251 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Bottom 25%
Fair Value upside −12% · Below median
Profitability
Return on assets 0% · Bottom 25%
Net margin (TTM) −13% · Bottom 25%
Operating margin (TTM) 7% · Below median
Growth and dividend
Revenue growth −10% · Bottom 25%

Valuation Multiplesvs Household & Personal Products median · lower = cheaper

P/B 2.28× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 0.86× · Cheaper than median
EV/EBITDA 18.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)18 · sector 33
FUTURE (revenue growth)0 · sector 5
PAST (return on equity)0 · sector 27
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 55

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Colgate-Palmolive Company CL $85.93 $55.95 −35%
Hindustan Unilever Limited HINDUNILVR ₹1,950 ₹775.25 −60%
Kenvue Inc KVUE $17.86 $12.73 −29%
Kimberly-Clark Corporation KMB $97.70 $83.93 −14%
Henkel AG HEN €68.50 €80.96 +18%
The Estée Lauder Companies Inc EL $98.83 $27.22 −72%
Church & Dwight Co CHD $96.02 $65.12 −32%
Beiersdorf Aktiengesellschaft, BEI €78.18 €68.95 −12%
Puig Brands, S.A PUIG €17.56 €19.32 +10%
Godrej Consumer Products Limited GODREJCP ₹879.75 ₹700.08 −20%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Anagenics Ltd · Fair Value
A$0.0053 −13%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Anagenics Ltd Fair Value". https://www.fairvalue-calculator.com/stock/AN1

Frequently asked questions

Is Anagenics Ltd (AN1) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of A$0.0053 versus a price of A$0.0060, about −12% upside (overvalued).
What is the fair value of AN1?
Our model-based fair value for Anagenics Ltd is A$0.0053 (as of Sep 13, 2026), built from audited fundamentals. The current price: A$0.0060.
What is the quality score of AN1?
Anagenics Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anagenics Ltd (AN1)?
Our model-based price target is the fair value of A$0.0053 (as of Sep 13, 2026) from 2 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Anagenics Ltd stock forecast for 2026?
Our models put fair value at A$0.0053, about −12% upside versus a price of A$0.0060 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Anagenics Ltd (AN1)?
Anagenics Ltd reported trailing-twelve-month revenue of about A$4.8M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Anagenics Ltd (AN1)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anagenics Ltd it is A$0.0053 per share (as of Sep 13, 2026), against a price of A$0.0060. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Anagenics Ltd stock overvalued or undervalued in 2026?
As of Sep 13, 2026, AN1 trades above its calculated fair value: price A$0.0060, fair value A$0.0053, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AN1?
No. The price is what the market pays today (A$0.0060); the fair value is what the company's own numbers justify (A$0.0053). For Anagenics Ltd the two are A$0.0007 per share apart. That gap is exactly why we show both numbers side by side.
How much is Anagenics Ltd worth?
The market values Anagenics Ltd at about A$5.9M (market capitalisation, as of Sep 13, 2026). Per share that is A$0.0060; our models calculate a fair value of A$0.0053 per share.
How solid is the balance sheet of Anagenics Ltd (AN1)?
Balance-sheet figures for Anagenics Ltd (as of Sep 13, 2026): return on equity −28.5%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is AN1 from its 52-week high?
Anagenics Ltd trades at A$0.0060, about 33% below its 52-week high of A$0.0090 and 50% above the low of A$0.0040 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0053 is for.
Which stocks are comparable to Anagenics Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, Kimberly-Clark Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anagenics Ltd stock attractive at the current price?
The data as of Sep 13, 2026: price A$0.0060, calculated fair value A$0.0053 (−12%), Quality Score 42/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AN1 calculated?
We run Anagenics Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0053, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Anagenics Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anagenics Ltd (AN1)?
The closing price on Sep 24, 2026 was A$0.0060. Our model-based fair value is A$0.0053, about −12% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anagenics Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Anagenics Ltd

How large is the market capitalisation of Anagenics Ltd (AN1)?
The market capitalisation of Anagenics Ltd is A$5.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Anagenics Ltd (AN1)?
The price-to-sales ratio of Anagenics Ltd is 1.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Anagenics Ltd (AN1)?
The net margin of Anagenics Ltd is −26.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Anagenics Ltd (AN1)?
The return on equity (ROE) of Anagenics Ltd is −28.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anagenics Ltd (AN1)?
On an EBIT basis the return on assets of Anagenics Ltd is −41.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Anagenics Ltd (AN1)?
The operating margin of Anagenics Ltd is 6.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Anagenics Ltd (AN1)?
Revenue at Anagenics Ltd is growing −10.0% versus a year earlier (3y avg −11.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Anagenics Ltd (AN1) generate?
The free cash flow of Anagenics Ltd is −A$1.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Anagenics Ltd (AN1) carry?
The net debt of Anagenics Ltd is A$453K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Anagenics Ltd in the live analysis

One click puts Anagenics Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.